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S230 Poster Session Iallogeneic sibling matched bone marrow transplant in autumn 2005,
after ovarian tissue cryopreservation. The conditioning regimen in-
cluded IV busulfan (12.8 mg/kg total dose), cyclophosphamide
(200 mg/kg total dose) and antilymphocyte globulin. A stable
100% donor chimerism was obtained from D60. An acute grade II
GVHDwas followed by limited chronic GVHD for 7 months. Clin-
ical menopause with amenorrhoea due to premature ovarian failure
occured within the first year post-HSCT. Hormone replacement
with oestro-progestogens was started 6 months after HSCT and
was maintained until ovarian function restoration. In spring 2008,
as the patient had been menopausal for 2.5 years, an orthotopic au-
totransplantation of ovarian cortex was performed in two consecu-
tive laparoscopic procedures, the first one being aimed at inducing
local angiogenesis. One thawed strip of ovarian cortex was fixed in
the ovarian incision, 5 others were deposited in the peritoneal win-
dow. Three days later, 3 thawed cortical strips were fixed into the
left ovary and one into the peritoneal window. Ovarian function re-
covery was evaluated by hormonal levels and follicular development
was observed by ultrasound.
The patient conceived spontaneously in a natural cycle in autumn
2008, and delivered a healthy child in June 2009. This first case re-
port of pregnancy and delivery after ovarian autograft in a patient
treated by HSCT suggests that cryopreservation of ovarian tissue
should be offered prior to HSCT not only to women of childbearing
age but also to prepubertal patients, as primordial follicles are al-
ready present in the post natal ovaries.194
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Background:Nearly 90% of the patients who are alive 2 years af-
ter allogeneic SCT (allo-SCT) will become long term survivors
and the focus of care moves to the long term complications.
Chronic graft-versus-host-disease (cGVHD) has attracted the
most attention, especially non-infectious pulmonary complication
bronchiolitis obliterans (BO). Extracorporeal Photopheresis
(ECP), has been shown to be a promising treatment for cGVHD,
however, only a few case reports are available that examines the ef-
fectiveness of ECP for BO.
Methods:Nine patients received ECP between 7/2008-8/2009 after
median follow-up of 23 months (range 9-93) for symptomatic BO
who failed immunosuppressive therapy and combination with azi-
thromycin, inhaled steroids6montelucast sodium. Records were re-
viewed to determine the impact of ECP on BO in an IRB-approved
study. Patients were treated on a weekly basis with 2 pheresis sessions
a week (3 to 4 weeks) and then decreased to an every 2 to 4 week
interval. (Jagasia et al Biol Blood Marrow Transplant 2009;15:
1288-95).
Results: All except one patient received allo-SCT for hematological
malignancies. Themedian age was 38 years (range 21-54), and 5were
female. Patients received allo-SCT between 1/2002- 6/2008 from
matched related (n5 5) or unrelated donor (n5 4); conditioning
consisted TBI based myeloablative regimens in 7 patients. GVHD
prophylaxis consisted of calcineurin inhibitors and methotraxate or
mycophenolate. Grade II-IV aGVHD occurred in 8 patients, grade
III in 1. All patients experienced cGVHD, 3 patients had 5 organ in-
volvements (median 3, range 1-5). Pre-ECP cGVHD pulmonary
subscale score was 3 in 4 (44%) patients. Median time to BO was
17 months post-transplant (range 5-46). All patients had minimum
of 4 drug regimens prior to ECP (median 5, range 4-6) for BO man-
agement. Median time to ECP following diagnosis of BO was 3
months (range 1-54). Eight of 9 (89%) responded to ECP after a me-
dian of 25 days (range 20-958). One patient who did not qualify as
responder had stabilization in FEV1 but continue to remain symp-
tomatic after 108 day on ECP. Three of 4 patients with pulmonary
cGVHD score of 3 responded to addition of ECP.Conclusion: Our case series shows that addition of ECP to com-
monly used regimen for BO results in faster symptomatic improve-
ment in an otherwise debilitating long term complication after
allo- SCT. A limitation of this study is a small sample size, short fol-
low-up, however impressive clinical response.LEUKEMIA
195
IMATINIB MAINTENANCE FOLLOWING ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION (HCT) FOR PATIENTS WITH PHILADELPHIA
CHROMOSOME POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA
(ALL)
Kebriaei, P.1, Chiattone, A.1, Saliba, R.1, Jones, D.2, Anderlini, P.1,
Andersson, B.1, Khouri, I.1, Worth, L.3, Ravandi, F.4, Thomas, D.4,
Kantarjian, H.4, Hamerschlak, N.5, Rodrigues, M.5, de Lima, M.1,
Giralt, S.1, Champlin, R.1 1University of Texas M.D. Anderson Cancer
Center, Houston, TX; 2University of Texas M.D. Anderson Cancer Cen-
ter, Houston, TX; 3University of Texas M.D. Anderson Cancer Center,
Houston, TX; 4University of Texas M.D. Anderson Cancer Center, Hous-
ton, TX; 5Albert Einstein Israeli Hospital (HIAE), Sao Paulo, Brazil
The addition of tyrosine kinase inhibitors (TKI) to conventional
ALL therapy has significantly improved outcome for Ph+ patients,
resulting in more patients being able to receive HCT in remission.
Maintenance therapy with TKI following HCT may additionally
improve outcomes. We performed a retrospective chart review on
transplants since 2001 when TKI first became available for use fol-
lowing HCT. From March 2001 through June 2009, 66 patients
with median age 37 years (range 3-61) received an allogeneic HCT
for Ph+ ALL in CR1 (n5 56) or CR2 (n5 10); 28 patients were in
complete molecular remission at time of HCT. Patients received
matched related (n5 30) or matched unrelated (n5 27) peripheral
blood (n5 35), bone marrow (n5 22), or mismatched cord blood
cells (n5 9) following a myeloablative TBI-based (n5 48) or non-
TBI-based (n5 18) transplant conditioning regimen. GVHD pro-
phylaxis was tacrolimus-based. All patients received TKI prior to
HCT. Patients were eligible to receive TKI maintenance following
HCT if they had hematologic recovery defined by an unsupported
platelet count .50,000/uL and absolute neutrophil count .1500/
uL. Forty-seven percent (n5 31) of patients received TKI in the
form of imatinib at median dose 300 mg (range 100-800) initiated
at median of 2 months (range 1-12) following HCT. Median dura-
tion of imatinib use post HCT was 13 months (range 1-91). The
most common reason for treatment discontinuation was physician
preference followed by disease progression. Cytopenias and gastro-
intestinal discomfort were the most common imatinib-related toxic-
ities.With amedian follow-up of 4 years among survivors (range 0.3-
7.7), 2-year overall survival (OS) and progression-free survival (PFS)
were 55% and 50%, respectively. Day 100, 1-year, and 2-year non-
relapse mortality (NRM) rates were 11%, 26%, and 28%, respec-
tively. The cumulative incidence of grade 2-4 and 3-4 acute
GVHD were 48% and 16%, respectively; the incidence of chronic
extensive GVHD was 19%. In univariate analysis, imatinib mainte-
nance led to significantly better OS (HR 0.3, 95% CI 0.1-.8,
p5 0.02) and NRM (HR 0.3, 95%CI 0.1-1.1, p5 0.07). Addition-
ally, age. 40 years and CR2 vs CR1 led to significantly worse OS;
molecular remission did not reach statistical significance. Large,
multicenter trials in Ph+ ALL are in progress to confirm the benefit
of TKI maintenance following HCT.196
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Introduction: As Dendritic cells (DC) are effective conductors of
adaptive and innate immune responses, they are used as cellular ad-
juvant for active immunotherapy. Nevertheless, challenges to this
